Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Phase III ADAURA trial reveals promising results for patients with non-small cell lung cancer

Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years.

12 Sep 2022

Study identifies new therapeutic target against lung adenocarcinoma

The TIMP-1 protein levels in both tissues and blood have been repeatedly associated with a poor prognosis in lung cancers, but its role in this cancer process was, to date, unknown.

12 Sep 2022

Pollutant particles in the air trigger lung cancer in non-smokers

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies, according to late-breaking data [to be] reported at the ESMO Congress 2022 by scientists of the Francis Crick Institute and University College London, funded by Cancer Research UK. The particles, which are typically found in vehicle exhaust and smoke from fossil fuels, are associated with non-small cell lung cancer (NSCLC) risk, accounting for over 250,000 lung cancer deaths globally per year.

12 Sep 2022

Comprehensive genetic architecture atlas compiled for mutant RAS genes in cancers

Researchers at the Johns Hopkins Kimmel Cancer Center, three other cancer centers and the Johns Hopkins Bloomberg School of Public Health compiled a comprehensive genetic architecture atlas for mutant RAS genes in human cancers.

8 Sep 2022

CRISPR genome-editing technology can be used as a tool to discover RNA therapeutics for lung cancer

An international team of scientists have demonstrated for the first time that CRISPR genome-editing technology can be used as a tool to find new gene therapies for lung cancer.

24 Aug 2022

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.

8 Aug 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Study reveals the intertumoral heterogeneity of METex14 skipping positive NSCLCs

A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping.

8 Aug 2022

Sub lobar surgery found to be non-inferior to lobectomy for patients with small-sized peripheral NSCLC

A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Increased use of stereotactic body radiation therapy for NSCLC patients can reduce treatment disparities

The use of Stereotactic Body Radiotherapy (SBRT) for patients with non-small cell lung cancer can reduce treatment disparities between White and Black patients, according to research presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

New recommendations on how to determine eligibility criteria for lung cancer clinical trials

A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill clinical trials and enroll sufficiently diverse groups of patients for results to reflect the broader population, in part because of stringent guidelines on who can participate.

5 Aug 2022

Researchers report genomic profiling from more than 110,000 tumors

Researchers analyzed data from the latest public release of the GENIE project of the American Association for Cancer Research.

19 Jul 2022

The Mark Foundation for Cancer Research announces latest ASPIRE awards for eight outstanding projects

The Mark Foundation for Cancer Research announced eight outstanding research projects to receive its latest class of ASPIRE awards.

14 Jul 2022

Study: Certain genetic features predispose lung cancer patients to develop immunotherapy side effects

Lung cancer is the deadliest form of cancer, accounting for an estimated 1.8 million deaths worldwide.

14 Jul 2022

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

The NRG Oncology/Alliance clinical trial NRG-LU005, examining the addition of the immunotherapy drug atezolizumab combined with chemoradiation for patients with limited-stage small cell lung cancer (SCLC) recently reached the trial's accrual goal of 506 patients.

8 Jul 2022

Small Cell Lung Cancer News and Research

Phase III ADAURA trial reveals promising results for patients with non-small cell lung cancer

Study identifies new therapeutic target against lung adenocarcinoma

Pollutant particles in the air trigger lung cancer in non-smokers

Comprehensive genetic architecture atlas compiled for mutant RAS genes in cancers

CRISPR genome-editing technology can be used as a tool to discover RNA therapeutics for lung cancer

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Study reveals the intertumoral heterogeneity of METex14 skipping positive NSCLCs

Sub lobar surgery found to be non-inferior to lobectomy for patients with small-sized peripheral NSCLC

Increased use of stereotactic body radiation therapy for NSCLC patients can reduce treatment disparities

New recommendations on how to determine eligibility criteria for lung cancer clinical trials

Researchers report genomic profiling from more than 110,000 tumors

The Mark Foundation for Cancer Research announces latest ASPIRE awards for eight outstanding projects

Study: Certain genetic features predispose lung cancer patients to develop immunotherapy side effects

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

Innovative strategy for treating non-small cell lung cancer when radiotherapy fails

Study provides better understanding of how therapeutic resistance develops in lung cancer

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News